G1 Therapeutics to Present Phase 1b Data on G1T38 in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
125
G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

RESEARCH TRIANGLE PARK, N.C., May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with Faslodex ® (fulvestrant) will be presented in a poster session on June 2 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago, IL. These data showed promising safety and tolerability when G1T38 was dosed continuously as a treatment for people with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer.

G1T38 is an oral CDK4/6 inhibitor with broad therapeutic potential in many forms of cancer and may serve as backbone therapy for multiple combination regimens.

“The combination of G1T38 and Faslodex has been well tolerated in this Phase 1b clinical trial, with no treatment-related serious adverse events reported. CDK4/6 inhibition can cause dose-limiting neutropenia that may require a treatment holiday. Importantly, chronic use of G1T38 in this trial resulted in dose-dependent decreases in absolute neutrophil counts that plateaued after four to five weeks of therapy. This allowed for continuous dosing of G1T38 without a drug holiday,” said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. “The dose escalation portion of this clinical trial is ongoing, and we are encouraged by the early safety, tolerability and efficacy findings that support the continued development of G1T38 as a potential best-in-class oral CDK4/6 inhibitor.”

Details on the presentation are listed below and are also available on the 2018 ASCO Annual Meeting website: http://abstracts.asco.org/ .

Title: G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary Phase 1b results . Abstract Number: 1061 Session: Breast Cancer – Metastatic Poster Number : 142 Date / Time / Location: June 2, 8-11:30 a.m. CT; McCormick Place South, Hall A, Chicago, IL Presenter: Iurie Bulat, M.D. (ARENSIA Exploratory Medicine Research Unit, Institute of Oncology)

For more information about the 2018 ASCO Annual Meeting, please visit https://am.asco.org/ .

About G1T38 G1T38 is a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Preclinical data presented at the American Association for Cancer Research 2016 Annual Meeting and published in  Molecular Cancer Research  and  Oncotarget  demonstrated the compound’s differentiation from other CDK4/6 inhibitors.

G1T38 is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with Faslodex ®  for people with ER+, HER2- breast cancer ( NCT02983071 ), and a trial in combination with Tagrisso ®  for people with EGFR-mutant non-small cell lung cancer ( NCT03455829 ).

About Faslodex ® Faslodex, developed and commercialized by AstraZeneca, represents a hormonal treatment approach that helps to slow tumor growth by blocking and degrading the estrogen receptor – a key driver of disease progression. Faslodex is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on anti-estrogen therapy.

Faslodex has also been licensed for use with CDK4/6 inhibitors, palbociclib (in the U.S., EU and several other markets) and abemaciclib (in the U.S. only) for the treatment of women with ER+, HER2- advanced breast cancer, whose cancer has progressed after endocrine therapy. In Japan, Faslodex is also approved for use in combination with any CDK4/6 inhibitor.

About G1 Therapeutics G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company’s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com  and follow us on Twitter @G1Therapeutics.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, G1T38 and G1T48, and are based on G1 Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; G1 Therapeutics’ ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; G1 Therapeutics’ ability to recruit and enroll patients in its studies; competition in the industry in which G1 Therapeutics operates; and market conditions. Except as required by law, G1 Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact: Jeff Macdonald Head of Investor Relations / Public Relations 917-371-0940 jmacdonald@g1therapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 52

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 21

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 0

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 34

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 54

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading

Top 5 Most Recently Viewed Articles

Duos Technologies Secures $40 Million Offering for Growth

Updated Category News Views 263

Duos Technologies Announces Successful Pricing of Public Offering Duos Technologies Group, Inc. (Nasdaq: DUOT) has successfully priced its public offering of common stock, raising $40 million to expand its operations and address its ambitious revenue goals. Overview of the Offering In a recent announcement, Duos unveiled that it will be offering 6,666,667 shares of its...

Continue Reading
Understanding TELUS Intl's Upcoming Earnings Report

Updated Category News Views 170

TELUS Intl Quarterly Earnings Overview TELUS Intl (TIXT) is preparing to unveil its quarterly earnings report, sparking interest among investors keen on understanding the company's performance and future outlook. As we approach the announcement, anticipation grows regarding the possible results and guidance. Investor Expectations Analysts have set their eyes on TELUS...

Continue Reading
America's Car-Mart Reports Q1 Results and Strategic Focus

Updated Category News Views 70

America's Car-Mart Focuses on Strategic Growth Amid Revenue Declines America's Car-Mart Inc. (NASDAQ: CRMT), a leading automotive retailer in the United States, has recently released its financial results for the first quarter of fiscal 2025. The company reported a revenue decline of 5.2%, primarily due to a decrease in retail units sold. However, America's Car-Mart is...

Continue Reading
Kayne Anderson Energy Infrastructure Fund Declares New Share Distribution

Updated Category News Views 108

Distribution Announcement from Kayne Anderson Energy Infrastructure Fund Kayne Anderson Energy Infrastructure Fund, Inc. has officially announced a monthly distribution of $0.08 per share. This upcoming payment is scheduled for common stockholders and highlights the fund's commitment to providing returns to its investors. Details of the Monthly Distribution The...

Continue Reading
Giftify, Inc. Celebrates Revenue Growth and Strategic Advancements

Updated Category News Views 249

Revenue Highlights and Profit Growth Giftify, Inc. (NASDAQ: GIFT), a major player in the incentives and rewards industry, reported impressive financial results for the first quarter. The company's revenue soared by 3.5%, reaching $22.3 million, demonstrating its resilience in a competitive market. Moreover, the company's gross profit increased by 10%, now standing at $3.6...

Continue Reading